Overview
On September 17, 2025, Tonix Pharmaceuticals Holding Corp. announced the in-licensing of TNX-4800, a long-acting human monoclonal antibody targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease. This development is aimed at providing a prophylactic treatment for Lyme disease, particularly during the tick season in the U.S.
Key Highlights
Clinical Development
Positive Phase 1 Study: The initial study demonstrated safety, tolerability, and a linear pharmacokinetic: pharmacodynamic: efficacy relationship.
Adaptive Phase 2/3 Study Planned: Tonix is preparing for further clinical trials to evaluate TNX-4800’s efficacy and safety.
Lyme Disease Context
Prevalence: Approximately 70 million people in the U.S. are at risk for Lyme disease, particularly in endemic areas.
Current Landscape: There are no FDA-approved vaccines or prophylactics for Lyme disease, making TNX-4800 a potentially significant advancement.
Mechanism of Action
Targeting OspA: TNX-4800 binds to OspA, blocking the maturation of Borrelia burgdorferi in the midgut of infected ticks, thereby preventing transmission to humans.
Single-Dose Administration: The antibody is designed for annual use, providing protection shortly after administration and maintaining antibody levels throughout the tick season.
Statements from Leadership
Seth Lederman, M.D. (CEO): Emphasized the importance of TNX-4800 in preventing Lyme disease, highlighting its innovative single-dose approach.
Mark Klempner, M.D. (UMass Chan Medical School): Stressed the urgency of preventing Lyme disease and the safety and effectiveness of monoclonal antibodies in infection prevention.
Terence R. Flotte, M.D. (UMass Chan Medical School): Expressed pride in collaborating with Tonix to address the public health challenge posed by Lyme disease.
About Lyme Disease
Transmission and Symptoms: Lyme disease is transmitted through infected Ixodes ticks, with symptoms including fever, headache, fatigue, and a characteristic rash. If untreated, it can lead to severe complications affecting joints, heart, and nervous system.
Chronic Lyme Disease: Up to 20% of treated cases may develop Post-Treatment Lyme Disease Syndrome (PTLDS), characterized by persistent symptoms.
About Tonix Pharmaceuticals
Company Profile: Tonix is a fully-integrated biopharmaceutical company with a diverse pipeline, including treatments for fibromyalgia and other conditions.
Recent Approvals: The company recently received FDA approval for Tonmya™, a non-opioid analgesic for fibromyalgia.
Future Directions
Tonix plans to advance TNX-4800 through additional clinical trials, aiming for a Biologics Licensing Application (BLA) submission to the FDA.
Conclusion
The announcement of TNX-4800 represents a significant step forward in the fight against Lyme disease, offering a novel prophylactic option for millions at risk. The collaboration between Tonix Pharmaceuticals and UMass Chan Medical School highlights a commitment to innovative solutions in public health.
This patriotic themed short sleeve shirt is made of cotton, which is soft, skin friendly and has a delicate touch. It is not only durable and resistant to wear, but also highly breathable, keeping your skin dry and comfortable even in the hot summer.
